ALS/Neurodegenerative Program

About Spedding Research Solutions

Spedding Research Solutions operates a hybrid business model, combining fee-for-service CRO work in drug formulation and analytics with its own proprietary drug discovery programs. Its most advanced asset is a Phase 2-ready compound with orphan drug designation for ALS (Amyotrophic Lateral Sclerosis), derived from a novel pathway discovery. The company leverages the scientific reputation of its founder, Michael Spedding—a highly cited pharmacologist and Secretary-General of IUPHAR—to organize research consortia and pursue grants, positioning itself at the intersection of service provision and early-stage therapeutic development.

Therapeutic Areas